PHILADELPHIA—Short-term treatment with high-dose erythropoietin (EPO)—which is known to have tissue protective effects—does not decrease the incidence or duration of delayed graft function (DGF) or primary non-function (PNF) in recipients of kidneys from non-heart-beating donors, but it is associated with significantly better and faster renal recovery, a study found.